9 results about "CDH1" patented technology

The present invention relates to the systems and methods of identifying compounds to treat or prevent chronic obstructive pulmonary disorders (COPD). The present invention also provides compositions to treat or prevent COPD comprising modulators of one or more selected from the group consisting of: AC AN, ACTN1, ADAMTS4, ADRB2, AGER, AN06, AP3B1, AP0A1, ARRB1, ATP1A1, BCL2L1, BDKRB1, BRAF, CALCRL, CCL11, CDH1, CEACAM8, CHRM3, CHRNA1, CLU, COL10A1, COL12A1, COL14A1, COL4A2, COL6A1, COL6A3, COLGATE 1, CRH, CSK, CTSD, CTTN, CXCR1, CXCR4, CXCR5, FBN1, FGA, FGG, FHL2, FTH1, GNB1, GPIHBP1, GPR84, GPR97, GRM8, HAPLN1, H2BFS, HBB, HSP90B1, ICAM1, IGF1R, IL6, ITGA1, ITGAV, LAMA2, LAMA4, LRP1, LTBP1, MAPK3, MGAM, MMP1, MMP13, MMP3, MMP9, MYBPH, MYH10, MYH9, NMU, NR3C1, P4HB, PLCB3, PLAG2G7, POU2AF1, PPIB, PROK2, RUNX2, RXFP1, S100A12, S100P, SAA1, SDC2, SLC2A5, SMAD3, SPARCL1, SPP1, SYT13, TBX1, TF, TGFB2, THBS1, TIMP1, TLN1, TPM1, TPM2, TPM4, TSPAN14, TEN, TWIST2, VIM, and WT1, and methods of use thereof.

This article discloses a method for identifying the nature of thyroid nodules, including detecting the DNA methylation level in a sample selected from the following regions (1) and (2): (1) fragments of one or more of the following genes: GAS6, SOX17, ZMIZ1, TSHR, CDH1, MCRIP2, LINC01977, EGR3, and (2) nucleic acid regions within 10 kb upstream and downstream of the genes (1).

The application relates to the field of biotechnology, in particular to a probe composition for detecting a salivary gland tumor gene panel and application thereof, and further relates to a library construction method, a sequencing method, a kit and a device for the salivary gland tumor gene panel. The probe composition can capture nucleic acid molecules of multiple genes related to salivary gland tumors, such as AKT1, APC, AR, ARID1A, ATM, AXIN1, BAP1, BARD1, BCOR, BRAF, BRCA1, BRCA2, CDH1, CDK11B, CDKN2A, CDKN2B, CREBBP, CTNNB1, CYLD, EGFR and EP300. The nucleic acid molecules in a sample to be analyzed are captured by using the probe composition, and library construction and sequencing are carried out; and the analysis result of the sequencing data is helpful to improving the diagnosis accuracy of salivary gland tumors.

This invention relates to a composition for preventing colitis-associated colorectal cancer and controlling weight, comprising seahorse, laver, kelp, spirulina, Ulva procumbens, and Gracilaria in a specific ratio. This formula is based on traditional Chinese medicine theories such as "five colors entering the five internal organs," "five flavors entering the meridians," and "salt can soften hardness," while also considering the combined use of warming and cooling properties, and the integration of clearing and tonifying. Through the combination of various marine algae and seahorse, it achieves synergistic effects on multiple targets, including immune regulation, anti-inflammation, intestinal barrier repair, and weight control. The preparation method is simple and low-cost, suitable for large-scale production in food and dietary supplements. Animal experiments show that this composition can significantly slow weight gain in normal mice. In an AOM / DSS-induced colitis-associated colorectal cancer model, it can reduce the disease activity index, decrease the number of colon tumors, alleviate abnormal organ enlargement and intestinal pathological damage, downregulate inflammatory factors such as iNOS and Cox-2, and upregulate intestinal barrier-related factors such as Cdh1, demonstrating a good preventive intervention effect.

The invention relates to preparation and functional analysis of an anti-soluble human CDH1 nano antibody. Specifically, the invention provides a CDH1 protein targeting nano antibody, and the CDH1 protein targeting nano antibody comprises a CDR1 as shown in SEQ ID NO: 4, a CDR2 as shown in SEQ ID NO: 5, and a CDR3 as shown in SEQ ID NO: 6. The nano antibody has high affinity with CDH1 protein, has the characteristics of high stability, high water solubility and the like, can be used for developing pharmaceutical compositions for treating CDH1-mediated related diseases or symptoms, can also be used for developing CDH1 detection reagents or kits, provides potential efficient antibodies for research of CDH1-mediated related diseases, and has a wide application prospect. And a new treatment strategy and target are provided for tumors.

The present disclosure relates to a cosmetic composition containing an extract of Cyperus rotundus extracted using warm microbubbles. The extract inhibits nitric oxide (NO) production and exhibits excellent anti-inflammatory efficacy by inhibiting the expression of interleukin 6 (IL-6), cyclooxygenase-2 (COX-2), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α), which are inflammatory expression factors. In addition, the extract enhances the expression of aquaporin-3 (AQP-3), hyaluronan synthase 2 (HAS-2), claudin-1 (CLDN-1), cadherin 1 (CDH1), filaggrin (FLG), and involucrin (IVL), which are genes related to the skin barrier and moisturizing. Thus, when using the extract for cosmetic products, excellent effects can be exhibited in skin soothing, moisturizing, enhancement of the skin barrier, relief of irritation such as erythema, relief of pruritus, and the like, so the extract can be usefully applied to multi-care products that improve skin conditions.

The invention relates to the field of cancer, in particular breast cancer. In particular it relates to the field of immune system directed approaches for tumor reduction and control. Some aspects of the invention relate to vaccines, vaccinations and other means of stimulating an antigen specific immune response against a tumor in individuals. Such vaccines comprise neoantigens resulting from frameshift mutations that bring out-of-frame sequences of the GATA3, CDH1, MAP3K1, RUNX1, and TP53 genes in-frame. Such vaccines are also useful for ‘off the shelf’ use.

Disclosed herein is a method of identifying the nature of a thyroid nodule, comprising detecting the level of DNA methylation in a sample in a region selected from (1) and (2) below: (1) a fragment of one or more genes selected from the group consisting of NEURL1, RUSC1, IL17C, TSHR, DAPK, PAX5, IRX4, CDH1, (2) a nucleic acid region within 10 Kb upstream or downstream of the genes of (1).

This article discloses a method for identifying the nature of thyroid nodules, including detecting the DNA methylation level in a sample selected from the following regions (1) and (2): (1) fragments of one or more of the following genes: RARG, PRR15, DPYS, MCC, TBX15, TSHR, DAPK, CDH1, and (2) nucleic acid regions within 10 kb upstream and downstream of the gene (1).